{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:22:51Z","timestamp":1772119371770,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-024-05918-9","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T06:04:59Z","timestamp":1724479499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Atezolizumab- and bevacizumab -induced encephalitis in a patient with advanced hepatocellular carcinoma: a case report and literature review"],"prefix":"10.1007","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5373-2929","authenticated-orcid":false,"given":"Min","family":"Sagong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7124-0736","authenticated-orcid":false,"given":"Keun Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8950-0866","authenticated-orcid":false,"given":"Byoung Kuk","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"5918_CR3","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L et al (2018) Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360:k793","journal-title":"BMJ"},{"key":"5918_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138","journal-title":"Eur J Cancer"},{"key":"5918_CR4","doi-asserted-by":"publisher","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off\u2019 the immune system. Ther Adv Neurol Disord 11:1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"issue":"16","key":"5918_CR15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMra023009","volume":"349","author":"RB Darnell","year":"2003","unstructured":"Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349(16):1543\u20131554","journal-title":"N Engl J Med"},{"issue":"20","key":"5918_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020) Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"8","key":"5918_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"key":"5918_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1750-1172-2-22","volume":"2","author":"J Honnorat","year":"2007","unstructured":"Honnorat J, Antoine JC (2007) Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2:22","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"5918_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3988\/jcn.2019.15.2.259","volume":"15","author":"A Kim","year":"2019","unstructured":"Kim A, Keam B, Cheun H, Lee ST, Gook HS, Han MK (2019) Immune-checkpoint-inhibitor-Induced severe autoimmune encephalitis treated by Steroid and Intravenous Immunoglobulin. J Clin Neurol 15(2):259\u2013261","journal-title":"J Clin Neurol"},{"issue":"24","key":"5918_CR9","doi-asserted-by":"publisher","first-page":"e26377","DOI":"10.1097\/MD.0000000000026377","volume":"100","author":"B \u00d6zdirik","year":"2021","unstructured":"\u00d6zdirik B, Jost-Brinkmann F, Savic LJ, Mohr R, Tacke F, Ploner CJ et al (2021) Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: case report and literature review. Med (Baltim) 100(24):e26377","journal-title":"Med (Baltim)"},{"issue":"9","key":"5918_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4065\/mcp.2010.0099","volume":"85","author":"Pelosof","year":"2010","unstructured":"Pelosof LC, Gerber DE (2010) Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 85(9):838\u2013854","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"5918_CR8","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2169\/internalmedicine.8919-21","volume":"61","author":"T Satake","year":"2022","unstructured":"Satake T, Maruki Y, Kubo Y, Takahashi M, Ohba A, Nagashio Y et al (2022) Atezolizumab-induced Encephalitis in a patient with Hepatocellular Carcinoma: a Case Report and Literature Review. Intern Med 61(17):2619\u20132623","journal-title":"Intern Med"},{"issue":"36","key":"5918_CR16","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 39(36):4073\u20134126","journal-title":"J Clin Oncol"},{"issue":"6","key":"5918_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81(6):772\u2013781","journal-title":"Ann Neurol"},{"issue":"26","key":"5918_CR1","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454","journal-title":"N Engl J Med"},{"issue":"6","key":"5918_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Ricard D, Psimaras D (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30(6):659\u2013668","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"5918_CR7","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","volume":"78","author":"R Velasco","year":"2021","unstructured":"Velasco R, Villagran M, Jove M, Simo M, Vilarino N, Alemany M et al (2021) Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol 78(7):864\u2013873","journal-title":"JAMA Neurol"},{"issue":"7","key":"5918_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","volume":"91","author":"A Vogrig","year":"2020","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B, Picard G, Rogemond V, Marchal C et al (2020) Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry 91(7):772\u2013778","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05918-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05918-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05918-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T15:04:43Z","timestamp":1727363083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05918-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["5918"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05918-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4644714\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Informed consent was obtained from the patient for the purpose of publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"397"}}